VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the U.S. Patent & Trademark Office (USPTO) has issued a Notice of Allowance for a U.S. Patent entitled “Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris.” Nodulocystic and conglobate acne are the most severe types of acne vulgaris, affecting some 8-10 million patients in the United States and producing scarring and substantial functional disability as a result of the scars.
“We are very pleased to receive the notice of allowance from the USPTO on this potential medical advance,” said Jeffrey Bernstein, Ph.D., President & Chief Executive Officer. “We believe our product has many advantages over oral isotretinoin therapy, which has been the principal treatment for these types of severe disfiguring acne vulgaris.”
Elorac plans to initiate a Phase II double-blind clinical trial of its once-weekly therapy during 2014.
About Elorac, Inc.
Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel prescription products for dermatology and oncology. The Company currently markets prescription dermatological products in the United States. Elorac has a very robust pipeline of prescription products in development, including naloxone hydrochloride lotion for the topical treatment of pruritus accompanying cutaneous T-cell lymphoma, a product candidate that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration and orphan drug designation from the European Medicines Agency (EMA). According to Inc. magazine’s 2013 list of fastest-growing private U.S. companies, Elorac ranked 23rd among health-care companies and No. 1 among pharmaceutical companies.